[{"id":"d3bfd11b-aa0d-4a68-9367-984e869fb8f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04712851","created_at":"2024-01-26T16:18:46.583Z","updated_at":"2025-02-25T12:27:53.681Z","phase":"Phase 2","brief_title":"Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia","source_id_and_acronym":"NCT04712851","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 06/30/2021","start_date":" 06/30/2021","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2025-02-24"},{"id":"c19f4f8d-399e-47b4-97ff-3f847081a79e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03469531","created_at":"2021-01-18T17:05:58.269Z","updated_at":"2024-07-02T16:37:07.967Z","phase":"Phase 2","brief_title":"Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer","source_id_and_acronym":"NCT03469531","lead_sponsor":"Zhujiang Hospital","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • TheraCIM (nimotuzumab)"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 03/20/2018","start_date":" 03/20/2018","primary_txt":" Primary completion: 03/10/2021","primary_completion_date":" 03/10/2021","study_txt":" Completion: 12/30/2021","study_completion_date":" 12/30/2021","last_update_posted":"2018-08-13"}]